AZD3470 Clinical Trials
2 recruitingDrug
Phase 12Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled33 locationsNCT06137144
Recruiting
Phase 1Phase 2
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca234 enrolled20 locationsNCT06130553